

Datasheet: HCA390

Description:	HUMAN ANTI AFLIBERCEPT
Specificity:	AFLIBERCEPT
Other names:	Eylea, Zaltrap
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD38778da
Isotype:	HuCAL Fab monovalent
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

A monovalent human recombinant Fab (lambda light chain) selected from the HuCAL phage display library, expressed in *E. coli*. The antibody is tagged with a DYKDDDDK tag and a double extended Strep-tag (SAWSHPQFEKGGGSGGGSGGSAWSHPQFEK) at the C-terminus of the antibody heavy chain. This antibody is supplied as a liquid.

Preparation

Metal chelate affinity chromatography

Source

E. coli

Buffer Solution

Phosphate buffered saline

Preservative Stabilisers

0.09% Sodium Azide (NaN₃)

Approx. Protein Concentrations

Antibody concentration 0.5 mg/ml

Immunogen

Aflibercept

Specificity

Human Anti-Aflibercept Antibody, clone AbD38778da is a recombinant antibody that specifically recognizes the fusion protein drug aflibercept as well as the vascular endothelial growth factor receptor 1 (VEGFR1). It does not recognize vascular endothelial growth factor receptor 2 (VEGFR2). It does not inhibit the binding of aflibercept to its target, the vascular endothelial growth factor (VEGF); it binds to both free aflibercept and aflibercept bound to its target VEGF and can be used to measure levels of aflibercept and its biosimilars in bioanalytical assays.

A pair of anti-aflibercept antibodies can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody, in monovalent Fab format, is recommended as the capture antibody, paired with the Human Anti-Aflibercept Antibody, clone AbD34644ia ([HCA386](#)) as the detection antibody.

Aflibercept (Eylea, Zaltrap) is a recombinant fusion protein consisting of the extra-cellular domain of human VEGF receptors 1 and 2, fused to the Fc portion of human IgG1. It is used to treat the 'wet' form of age-related macular degeneration (AMD) and impaired vision due to macular oedema. It is also used in the treatment of metastatic colorectal cancer in combination with 5-fluorouracil, leucovorin and irinotecan in patients previously treated with an oxaliplatin-containing chemotherapy. Aflibercept binds to circulating VEGF-A and VEGF-B to inhibit their ability to promote angiogenesis.

[View a summary of all anti aflibercept antibodies](#)

Affinity

The intrinsic affinity of the monovalent form of Human anti Aflibercept antibody, clone AbD38778da is $K_D = 4$ nM as measured by real time, label free molecular interaction analysis on immobilized Aflibercept

ELISA

Human anti Aflibercept antibody, clone AbD38778da can be used in an indirect ELISA. It can also be used as the capture antibody for aflibercept in a PK bridging ELISA together with [HCA386](#) as the detection antibody.

Protocol: [PK Bridging ELISA](#)

Storage

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

Guarantee

12 months from date of despatch

Acknowledgements

This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.
Eylea is a trademark of Regeneron/Sanofi.

Zaltrap is a trademark of Regeneron/Bayer Healthcare.

Health And Safety Information Material Safety Datasheet documentation #10040 available at:
<https://www.bio-rad-antibodies.com/SDS/HCA390>
10040

Licensed Use For *in vitro* research purposes and for commercial applications for the provision of *in vitro* testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

Regulatory For research purposes only

Technical Advice Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#).
This antibody contains a Strep-tag and will react with streptavidin.

Related Products

Recommended Useful Reagents

[HUMAN ANTI AFLIBERCEPT \(HCA386\)](#)

[HUMAN ANTI AFLIBERCEPT \(HCA387\)](#)

[HUMAN ANTI AFLIBERCEPT \(HCA388\)](#)

[HUMAN ANTI AFLIBERCEPT \(HCA389\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

'M432884:240913'

Printed on 13 Sep 2024

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)